Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Alzheimer's Disease

  Free Subscription


Articles published in Am J Psychiatry

Retrieve available abstracts of 17 articles:
HTML format



Single Articles


    June 2020
  1. SALZMAN C
    Do Benzodiazepines Cause Alzheimer's Disease?
    Am J Psychiatry. 2020;177:476-478.
    PubMed    


    December 2019
  2. NAPARSTEK S, Linkovski O, O'Hara R
    The Future of Dementia Biomarkers Needs Better Neuropsychology.
    Am J Psychiatry. 2019;176:1050.
    PubMed    


    July 2019
  3. JOHNSON SC, Asthana S
    Predicting Risk for Dementia: Is It Ready for the Clinic?
    Am J Psychiatry. 2019;176:501-502.
    PubMed    


    August 2018
  4. KOLLA BP, Mansukhani MP
    Methylphenidate and Apathy in Alzheimer's Disease: Is Sleep Apnea a Confounding Effect?
    Am J Psychiatry. 2018;175:792.
    PubMed    


  5. WION D
    The Temporal Relationship Between Alzheimer's Disease and Depressive Symptoms: Variable Matters.
    Am J Psychiatry. 2018;175:793.
    PubMed    


  6. PADALA PR, Dennis RA, Padala KP
    Addressing Possible Effects of Sleep Apnea in a Study of Methylphenidate for Apathy in Alzheimer's Disease: Response to Kolla and Mansukhani.
    Am J Psychiatry. 2018;175:792-793.
    PubMed    


    July 2018
  7. KRIVINKO JM, Erickson SL, Ding Y, Sun Z, et al
    Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease.
    Am J Psychiatry. 2018 Jul 19:appiajp201817080858.
    PubMed     Abstract available


    June 2018
  8. ROSENBERG PB, Lyketsos CG
    New Clues to Preclinical Alzheimer's Disease.
    Am J Psychiatry. 2018;175:493-494.
    PubMed    


    May 2018
  9. FARRELL M, Lichtenstein M, Crowley JJ, Filmyer DM, et al
    Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntington's Disease.
    Am J Psychiatry. 2018;175:400-407.
    PubMed    


    March 2018
  10. AXELRUD LK, Santoro ML, Pine DS, Talarico F, et al
    Polygenic Risk Score for Alzheimer's Disease: Implications for Memory Performance and Hippocampal Volumes in Early Life.
    Am J Psychiatry. 2018 Mar 2:appiajp201717050529.
    PubMed     Abstract available


    February 2018
  11. SULTZER DL
    Why Apathy in Alzheimer's Matters.
    Am J Psychiatry. 2018;175:99-100.
    PubMed    


    November 2017
  12. BARTELS C, Wagner M, Wolfsgruber S, Ehrenreich H, et al
    Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression.
    Am J Psychiatry. 2017 Nov 28:appiajp201717040404.
    PubMed     Abstract available


    September 2017
  13. PADALA PR, Padala KP, Lensing SY, Ramirez D, et al
    Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Am J Psychiatry. 2017 Sep 15:appiajp201717030316.
    PubMed     Abstract available


    April 2017
  14. LAVRETSKY H
    Hallucinations Predict Relapse After Discontinuation of Risperidone in Patients With Alzheimer's Disease and Psychosis or Agitation.
    Am J Psychiatry. 2017;174:307-308.
    PubMed    


  15. HILL NT, Mowszowski L, Naismith SL, Chadwick VL, et al
    Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis.
    Am J Psychiatry. 2017;174:329-340.
    PubMed     Abstract available


    March 2017
  16. TAYLOR WD
    Lack of a Role for Alzheimer's Disease Pathology in Late-Life Depression, or Just No Relationship With Amyloid?
    Am J Psychiatry. 2017;174:197-198.
    PubMed    


    November 2016
  17. PATEL AN, Lee S, Andrews HF, Pelton GH, et al
    Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations.
    Am J Psychiatry. 2016 Nov 18:appiajp201616020226.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: